{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:03:50Z","timestamp":1787321030242,"version":"build-2736575974"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bcp.2020.113894","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T11:56:25Z","timestamp":1583236585000},"page":"113894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?"],"prefix":"10.1016","volume":"177","author":[{"given":"Paolo","family":"Gelosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castiglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-3454","authenticated-orcid":false,"given":"Luigi","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.113894_b0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2020.113894_b0010","series-title":"Drug Repositioning","first-page":"33","article-title":"Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs","author":"Frail","year":"2012"},{"key":"10.1016\/j.bcp.2020.113894_b0015","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1039\/C5MB00306G","article-title":"Protein localization vector propagation: a method for improving the accuracy of drug repositioning","volume":"11","author":"Yeu","year":"2015","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.bcp.2020.113894_b0020","first-page":"1","article-title":"Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics","author":"Talevi","year":"2019","journal-title":"Exp. Opin. Drug Discov."},{"key":"10.1016\/j.bcp.2020.113894_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/minf.200900069","article-title":"Drug-target networks","volume":"29","author":"Vogt","year":"2010","journal-title":"Mol. Inform."},{"key":"10.1016\/j.bcp.2020.113894_b0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2020.113894_b0035","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.2147\/DDDT.S214907","article-title":"Minoxidil and its use in hair disorders: a review","volume":"13","author":"Suchonwanit","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2020.113894_b0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/ph11020057","article-title":"Changing trends in computational drug repositioning","volume":"11","author":"Yella","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2020.113894_b0050","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2020.113894_b0055","unstructured":"https:\/\/globalgenes.org\/rare-diseases-facts-statistics, n.d.."},{"key":"10.1016\/j.bcp.2020.113894_b0060","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1021\/acs.jmedchem.6b00078","article-title":"Impact of binding site comparisons on medicinal chemistry and rational molecular design","volume":"59","author":"Ehrt","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.113894_b0065","article-title":"Drug databases and their contributions to drug repurposing","author":"Masoudi-Sobhanzadeh","year":"2019","journal-title":"Genomics"},{"key":"10.1016\/j.bcp.2020.113894_b0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.compbiolchem.2015.09.010","article-title":"In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an experimental target","volume":"59","author":"Rashmi","year":"2015","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.113894_b0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/bib\/bbr013","article-title":"Exploiting drug-disease relationships for computational drug repositioning","volume":"12","author":"Dudley","year":"2011","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.bcp.2020.113894_b0080","doi-asserted-by":"crossref","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","article-title":"Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease","volume":"3","author":"Dudley","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0085","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/cvr\/cvn120","article-title":"Cytokines and atherosclerosis: a comprehensive review of studies in mice","volume":"79","author":"Kleemann","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2020.113894_b0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00228-017-2242-2","article-title":"The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field","volume":"73","author":"Hoxha","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0100","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaci.2011.11.052","article-title":"Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease","volume":"129","author":"Ingelsson","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2020.113894_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2432958","article-title":"Role of the cysteinyl leukotrienes in the pathogenesis and progression of cardiovascular diseases","volume":"2017","author":"Colazzo","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.bcp.2020.113894_b0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.phrs.2019.02.025","article-title":"Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug","volume":"142","author":"Gelosa","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2020.113894_b0115","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mad.2018.07.006","article-title":"Proinflammatory cytokines and ageing of the cardiovascular-renal system","volume":"175","author":"Smykiewicz","year":"2018","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.bcp.2020.113894_b0125","doi-asserted-by":"crossref","first-page":"e7308","DOI":"10.1097\/MD.0000000000007308","article-title":"Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts","volume":"96","author":"Fern\u00e1ndez-Guti\u00e9rrez","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2020.113894_b0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/intimm\/dxv063","article-title":"Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases","volume":"28","author":"Lai","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bcp.2020.113894_b0135","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.bcp.2020.113894_b0140","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2015-208995","article-title":"Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis","volume":"75","author":"Ljung","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2020.113894_b0145","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","article-title":"Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-\u03b1 blockers and traditional disease-modifying antirheumatic drugs","volume":"31","author":"Di Minno","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcp.2020.113894_b0150","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3899\/jrheum.120541","article-title":"Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis \u2013 a randomized trial","volume":"39","author":"Tam","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2020.113894_b0155","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/rheumatology\/ket469","article-title":"The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis \u2013 a randomized, placebo-controlled pilot trial","volume":"53","author":"Tam","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2020.113894_b0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1527-5299.2002.01155.x","article-title":"The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure","volume":"8","author":"Lisman","year":"2002","journal-title":"Congest. Heart Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0165","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0170","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0175","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0180","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0185","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0008-6363(97)00309-X","article-title":"Tumor necrosis factor in CHF: a double facet cytokine","volume":"37","author":"Ferrari","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2020.113894_b0190","first-page":"CD012448","article-title":"TNF-\u03b1 blockers for the treatment of Kawasaki disease in children","volume":"8","author":"Yamaji","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bcp.2020.113894_b0195","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0200","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (recently decompensated heart failure anakinra response trial)","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0210","doi-asserted-by":"crossref","first-page":"e005036","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0215","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FJC.0000000000000378","article-title":"Interleukin-1 blockade in acute decompensated heart failure. A randomized, double-blinded, placebo-controlled pilot study","volume":"67","author":"Van Tassell","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0220","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0225","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/STROKEAHA.118.020750","article-title":"SCIL-STROKE (subcutaneous interleukin-1 receptor antagonist in ischemic stroke): a randomized controlled phase 2 trial","volume":"49","author":"Smith","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.bcp.2020.113894_b0230","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"CANTOS pilot investigative group, effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0235","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0240","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bcp.2020.113894_b0245","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/clc.23246","article-title":"Interleukin-1 blockade treatment decreasing cardiovascular risk","volume":"42","author":"Zheng","year":"2019","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0250","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2020.113894_b0255","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.bcp.2020.113894_b0260","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0265","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00296-017-3842-y","article-title":"Short-term application of tocilizumab during myocardial infarction (STAT-MI)","volume":"38","author":"Carroll","year":"2018","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bcp.2020.113894_b0270","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2020.113894_b0275","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0280","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.bcp.2020.113894_b0285","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ehf2.12487","article-title":"Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting","volume":"6","author":"Yano","year":"2019","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0290","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"FUTURE 1 study group, secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0295","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0300","article-title":"Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis","author":"Makavos","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0305","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52\u00a0weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2020.113894_b0310","first-page":"ced.14180","article-title":"Effect of biologics targeting IL-23\/IL-17 axis on subclinical atherosclerosis: results of a pilot study","author":"Marovt","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.bcp.2020.113894_b0315","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/med.20097","article-title":"Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin","volume":"28","author":"Bhattacharyya","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2020.113894_b0320","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine-Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2020.113894_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0923-1811(00)00097-9","article-title":"Colchicine and griseofulvin inhibit VCAM-1 expression on human vascular endothelial cells \u2013 evidence for the association of VCAM-1 expression with microtubules","volume":"25","author":"Asahina","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.bcp.2020.113894_b0330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.113894_b0335","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1476-5381.2011.01254.x","article-title":"Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action","volume":"163","author":"Marques-da-Silva","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0340","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tcm.2014.09.011","article-title":"Colchicine for pericarditis","volume":"25","author":"Imazio","year":"2015","journal-title":"Trends Cardiovasc. Med."},{"issue":"2015","key":"10.1016\/j.bcp.2020.113894_b0345","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"ESC guidelines for the diagnosis and management of pericardial diseases","volume":"36","author":"Adler","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0350","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12872-019-1195-z","article-title":"Correction to: Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome","volume":"19","author":"Lutschinger","year":"2019","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.bcp.2020.113894_b0355","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2020.113894_b0360","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2020.113894_b0365","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0370","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0375","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/0735-1097(92)90624-V","article-title":"Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty","volume":"19","author":"O\u2019Keefe","year":"1992","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0380","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients","volume":"61","author":"Deftereos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0385","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11239-011-0637-y","article-title":"Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial","volume":"33","author":"Raju","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.bcp.2020.113894_b0390","doi-asserted-by":"crossref","first-page":"e002128","DOI":"10.1161\/JAHA.115.002128","article-title":"Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome","volume":"4","author":"Mart\u00ednez","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2020.113894_b0395","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.clinthera.2019.07.015","article-title":"Colchicine as a novel therapy for suppressing chemokine production in patients with an acute coronary syndrome: a pilot study","volume":"41","author":"Tucker","year":"2019","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcp.2020.113894_b0400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.bcp.2020.113894_b0405","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0410","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.acvd.2016.10.004","article-title":"COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response","volume":"110","author":"Akodad","year":"2017","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.bcp.2020.113894_b0415","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchf.2013.11.006","article-title":"Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study","volume":"2","author":"Deftereos","year":"2014","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0425","first-page":"1024","article-title":"Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases","volume":"17","author":"B\u0103l\u0103nescu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0430","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0435","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2020.113894_b0440","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/1074248417699884","article-title":"MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS: a randomized double-blind, placebo-controlled trial (TETHYS Trial)","volume":"22","author":"Moreira","year":"2017","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113894_b0445","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0450","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","article-title":"Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data","volume":"27","author":"Nesti","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.bcp.2020.113894_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102863","article-title":"Metformin: an old drug with new applications","volume":"19","author":"Zhou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2020.113894_b0460","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/aps.2010.229","article-title":"Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation","volume":"32","author":"Fu","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2020.113894_b0465","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jama.2014.3315","article-title":"GIPS-III Investigators, Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial","volume":"311","author":"Lexis","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2020.113894_b0470","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S2213-8587(13)70152-9","article-title":"Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial","volume":"2","author":"Preiss","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bcp.2020.113894_b0475","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S2213-8587(15)00121-7","article-title":"Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial","volume":"3","author":"El Messaoudi","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bcp.2020.113894_b0480","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000355574","article-title":"Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention","volume":"127","author":"Li","year":"2014","journal-title":"Cardiology"},{"key":"10.1016\/j.bcp.2020.113894_b0485","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/eurjhf\/hfs106","article-title":"The effect of metformin on insulin resistance and exercise parameters in patients with heart failure","volume":"14","author":"Wong","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0490","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1093\/eurheartj\/ehz203","article-title":"A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial","volume":"40","author":"Mohan","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0495","article-title":"ABLE-MET investigators, effects of metformin on left ventricular size and function in hypertensive patients with type 2 diabetes mellitus: results of a randomized, controlled, multicenter, phase IV trial","author":"Ono","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"10.1016\/j.bcp.2020.113894_b0500","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis","volume":"18","author":"Han","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2020.113894_b0505","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1755-5922.12000","article-title":"GLP-1 receptor agonists: effects on cardiovascular risk reduction","volume":"31","author":"Lorber","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.bcp.2020.113894_b0510","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc10-1393","article-title":"Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2020.113894_b0515","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-10-22","article-title":"Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes","volume":"10","author":"Ratner","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2020.113894_b0520","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"L\u00f8nborg","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0525","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/db13-1849","article-title":"Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study","volume":"63","author":"L\u00f8nborg","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2020.113894_b0530","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4244\/EIJV12I4A78","article-title":"A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction","volume":"12","author":"Kyhl","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.bcp.2020.113894_b0535","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcp.2020.113894_b0540","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","article-title":"Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"170","author":"Chen","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0545","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005146","article-title":"Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction","volume":"9","author":"Chen","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.bcp.2020.113894_b0550","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12020-015-0798-0","article-title":"Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction","volume":"52","author":"Chen","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.bcp.2020.113894_b0555","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bph.13749","article-title":"Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia\/reperfusion injury and for treating heart failure","volume":"175","author":"Korkmaz-Ic\u00f6z","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0560","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/01.CIR.0000027149.83473.B6","article-title":"Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction","volume":"106","author":"Bocchi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0565","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijcard.2014.01.102","article-title":"PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials","volume":"172","author":"Zhuang","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0570","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12872-017-0576-4","article-title":"Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials","volume":"17","author":"Hwang","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.bcp.2020.113894_b0575","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ejhf.957","article-title":"Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements","volume":"19","author":"Hummel","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0580","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0585","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","article-title":"Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality","volume":"102","author":"Anderson","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.bcp.2020.113894_b0590","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/heartjnl-2016-310746","article-title":"Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction","volume":"103","author":"Andersson","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.bcp.2020.113894_b0595","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40264-014-0161-z","article-title":"Cardiovascular effects of drugs used to treat Alzheimer\u2019s disease","volume":"37","author":"Howes","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.bcp.2020.113894_b0600","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.2010.98","article-title":"The effect of donepezil treatment on cardiovascular mortality","volume":"88","author":"Sato","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113894_b0605","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FJC.0b013e3182609a74","article-title":"Influences of donepezil on cardiovascular system\u2013possible therapeutic benefits for heart failure\u2013donepezil cardiac test registry (DOCTER) study","volume":"60","author":"Kubo","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0610","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer\u2019s disease","volume":"34","author":"Nordstr\u00f6m","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0615","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000357124","article-title":"Cardioprotection and anticholinesterases in patients with Alzheimer\u2019s disease: time for reappraisal","volume":"4","author":"Monacelli","year":"2014","journal-title":"Dement. Geriatr. Cognit. Dis. Extra"},{"key":"10.1016\/j.bcp.2020.113894_b0620","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.bcp.2020.113894_b0625","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/art.33369","article-title":"Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal","volume":"64","author":"Neogi","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"2015","key":"10.1016\/j.bcp.2020.113894_b0630","first-page":"531","article-title":"Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet","volume":"65","author":"Jia","year":"1979","journal-title":"Hypertension (Dallas, Tex)"},{"key":"10.1016\/j.bcp.2020.113894_b0635","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/hrt.2004.040477","article-title":"Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure","volume":"91","author":"Gavin","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.bcp.2020.113894_b0640","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cardfail.2006.05.005","article-title":"The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study","volume":"12","author":"Cingolani","year":"2006","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.bcp.2020.113894_b0645","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0650","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"NHLBI heart failure clinical research network, effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.113894_b0655","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0975-3583.74262","article-title":"Allopurinol and global left myocardial function in heart failure patients","volume":"1","author":"Nasr","year":"2010","journal-title":"J. Cardiovasc. Dis. Res."},{"key":"10.1016\/j.bcp.2020.113894_b0660","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archinternmed.2010.198","article-title":"Gout, allopurinol use, and heart failure outcomes","volume":"170","author":"Thanassoulis","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcp.2020.113894_b0665","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00005344-200305000-00005","article-title":"Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction","volume":"41","author":"Guan","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0670","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijcard.2009.08.037","article-title":"The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"145","author":"Rentoukas","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0675","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0002-8703(91)90950-M","article-title":"A randomized controlled trial of allopurinol in coronary bypass surgery","volume":"121","author":"Johnson","year":"1991","journal-title":"Am. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0680","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0003-4975(91)91433-V","article-title":"Influence of allopurinol on cardiac complications in open heart operations","volume":"52","author":"Rashid","year":"1991","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.bcp.2020.113894_b0685","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1053-0770(96)80141-8","article-title":"Failure of allopurinol to improve left ventricular stroke work after cardiopulmonary bypass surgery","volume":"10","author":"Coetzee","year":"1996","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.bcp.2020.113894_b0690","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/hrt.71.2.177","article-title":"Lack of cardioprotective efficacy of allopurinol in coronary artery surgery","volume":"71","author":"Taggart","year":"1994","journal-title":"Br. Heart J."},{"key":"10.1016\/j.bcp.2020.113894_b0695","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jtcvs.2017.08.115","article-title":"Effect of administration of allopurinol on postoperative outcomes in patients undergoing intracardiac repair of tetralogy of Fallot","volume":"155","author":"Talwar","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.bcp.2020.113894_b0700","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FJC.0000000000000409","article-title":"The impact of allopurinol on patients with acute ST elevation myocardial infarction undergoing thrombolytic therapy","volume":"68","author":"Separham","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113894_b0705","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.hjc.2017.01.004","article-title":"Clinical Study on efficacy of allopurinol in patients with acute coronary syndrome and its functional mechanism","volume":"58","author":"Huang","year":"2017","journal-title":"Hellenic J. Cardiol."},{"key":"10.1016\/j.bcp.2020.113894_b0710","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial","volume":"300","author":"Feig","year":"2008","journal-title":"JAMA"},{"issue":"2012","key":"10.1016\/j.bcp.2020.113894_b0715","first-page":"1148","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"1979","journal-title":"Hypertension (Dallas, Tex)"},{"issue":"2016","key":"10.1016\/j.bcp.2020.113894_b0720","first-page":"535","article-title":"Allopurinol and cardiovascular outcomes in adults with hypertension","volume":"67","author":"MacIsaac","year":"1979","journal-title":"Hypertension (Dallas, Tex)"},{"key":"10.1016\/j.bcp.2020.113894_b0725","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1097\/HJH.0000000000002189","article-title":"Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension","volume":"37","author":"Gingles","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2020.113894_b0730","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12432","article-title":"Allopurinol and endothelial function: a systematic review with meta-analysis of randomized controlled trials","volume":"36","author":"Alem","year":"2018","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.bcp.2020.113894_b0735","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12872-017-0513-6","article-title":"Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes","volume":"17","author":"Singh","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.bcp.2020.113894_b0740","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","article-title":"Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Bredemeier","year":"2018","journal-title":"BMC Cardiovasc. Disord."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:22:22Z","timestamp":1757769742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220301222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":148,"alternative-id":["S0006295220301222"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113894","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113895","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113894"}}